12 Cheap Biotech Stocks Smart Investors Are Piling Into

Published on October 20, 2023 at 12:08 pm by Ramish Cheema in Hedge Funds, News

In this piece, we will take a look at 12 cheap biotechnology stocks that smart investors are piling into. If you want to skip our introduction to the biotechnology industry and how it might be affected by recent economic and stock market trends, then check out 5 Cheap Biotech Stocks Smart Investors Are Piling Into.

Biotechnology is one of the hottest industries these days and one that has grown in prominence and relevance in the aftermath of the coronavirus pandemic. As a primer, biotechnology refers to the processes and techniques used to develop medicines and drugs from biological raw materials. These helped companies such as Moderna, Inc. (NASDAQ:MRNA) and BioNTech SE (NASDAQ:BNTX) to develop messenger ribonucleic acid (mRNA) vaccines that enabled a reduction in the burden of coronavirus patients that hospitals were facing.

These mRNA vaccines also made headlines in October as the Nobel Assembly decided to award the 2023 Nobel Prize in Physiology and Medicine to researchers who played a crucial role in our understanding of how mRNA vaccines work in the human body. The two latest Nobel Prize winners, researchers Katalin Karikó and Drew Weissman, played a crucial role in mRNA development as they were able to devise an approach that prevents the human body’s immune system from attacking the mRNA molecules in a vaccine which prevents it from fighting diseases by enabling the creation of new antibodies.

However, as promising as the biotechnology industry is, the fact still remains that it is one of the most sensitive to high interest rates and a tough economic environment. Before they can be sold to pharmacies or provided to doctors, vaccines and drugs must go through intense research and development which require investing large sums of money with no absolute guarantee of future successful commercialization. Not to mention, higher interest rates aren’t helpful to biotechnology stocks either since they increase the discount rate applied to valuation models and make future cash flows less valuable. As an illustration of this fact, consider a biotechnology company that is projected to bring $100 million in free cash flow over the next ten years. In order to gauge the present value of this future money, it is divided by a discount rate which is influenced by interest rates.

If this discount rate is 10%, then the present value of these cash flows is $38.5 million, but if the rate is 20% then the present value drops to $16.2 million. Since a stock price is a reflection of investor expectations of the future, then a high rate environment naturally depresses stocks as firms have to scale up their cash generation in order to meet market expectations during a low rate environment as investors demand more compensation to not park their money in safer investments such as bonds and bank accounts.

Since we’re on the topic of interest rates, the close of the first week of October gave a shocker to markets that show that there really is no peace when it comes to being an analyst or an investor. The reason that rates are high right now is that the Federal Reserve is trying to reduce spending in the economy, by both businesses and consumers, to reduce the demand for products and services and bring down inflation. A key barrier that limits the Fed’s ability to raise the interest rates is economic strength as too high rates can very well tip the economy into a recession. Therefore, if the economy continues to grow, as it did in the second quarter at a rate of 2.1%, and if the labor market continues to add jobs, then the central bank finds more room to raise rates.

So, about the shocker. A key determinant of the interest rate decisions is the labor market, as when firms hire aggressively, they pay out higher salaries, which then contributes to more discretionary spending cash in the economy. On this front, the month started out with a private payrolls from ADP which showed that private employers added 89,000 new jobs in September for the slowest growth since mid 2021 and nearly half of the estimate provided by Dow Jones economists. For the stock market, this was good news as it suggested that the labor market might be cooling down to provide the Fed room to make a pause. However, data from the Labor Department that measures non farm employment in the United States showed that non farm payrolls grew by a whopping 336,000 in September, which was nearly double what economists had projected.

Amidst this backdrop, we decided to see which biotechnology stocks are cheap and are seeing interest from smart money investors. Some top names are Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), United Therapeutics Corporation (NASDAQ:UTHR), and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Photo by CDC on Unsplash

Our Methodology

To compile our list of the cheap biotechnology stocks that smart investors are buying, we first made a list of the most valuable biotechnology stocks with a price to trailing earnings ratio lesser than 50 and a market capitalization greater than $300 million. This makes them cheaper than the industry trailing P/E average of 113.8. Then, the companies with the highest number of hedge fund investors in Q2 2023 were determined and the top biotechnology stocks are as follows.

Cheap Biotech Stocks Smart Investors Are Piling Into

12. Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Number of Hedge Fund Investors In Q2 2023: 20

P/E Ratio: 4.79

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) is a biotechnology company based in Bermuda that develops treatments for heart diseases and arthritis. The firm’s shares are up by 14.75% year to date, and analysts have rated the stock as Strong Buy on average as well as set a $9 share price upside based on the average share price.

By the end of this year’s second quarter, 20 out of the 910 hedge funds part of Insider Monkey’s database were Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)’s investors. David Rosen’s Rubric Capital Management is the biggest shareholder among these since it owns 3.3 million shares that are worth $47.5 million.

11. BioNTech SE (NASDAQ:BNTX)

Number of Hedge Fund Investors In Q2 2023: 21

P/E Ratio: 5.97

BioNTech SE (NASDAQ:BNTX) was one of the first to develop a vaccine for the coronavirus. It also develops treatments for cancer and other diseases. However, the firm’s share price is down by 25% year to date as COVID euphoria surrounding the stock fades. The average share price target is still $50 higher than the current share price.

As of Q2 2023, 21 hedge funds among the 910 tracked by Insider Monkey had held a stake in the company. BioNTech SE (NASDAQ:BNTX)’s largest investor is Jim Simons’ Renaissance Technologies through its $48 million stake.

10. Zymeworks Inc. (NASDAQ:ZYME)

Number of Hedge Fund Investors In Q2 2023: 22

P/E Ratio: 5.97

Zymeworks Inc. (NASDAQ:ZYME) is a Canadian biotechnology company with several treatments in different trial phases for cancer, inflammatory diseases, and others. The firm is currently expanding its presence in Dublin, Ireland by opening a new European headquarters.

Insider Monkey dug through 910 hedge funds for their June quarter of 2023 shareholdings and discovered 22 Zymeworks Inc. (NASDAQ:ZYME) investors.

9. Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Number of Hedge Fund Investors In Q2 2023: 25

P/E Ratio: 21.92

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is an American firm that works with the building blocks of cells, enzymes. The firm’s second quarter results saw it grow its royalty revenue by 31% annually and it also scored a win in September when a drug made through its technology was approved in the U.K.

As of June 2023, 25 out of the 910 hedge funds part of Insider Monkey’s database had held a stake in the company. Out of these, Halozyme Therapeutics, Inc. (NASDAQ:HALO)s biggest shareholder is Paul Marshall and Ian Wace’s Marshall Wace LLP since it owns $83.8 million worth of shares.

8. POINT Biopharma Global Inc. (NASDAQ:PNT)

Number of Hedge Fund Investors In Q2 2023: 25

P/E Ratio: 6.23

POINT Biopharma Global Inc. (NASDAQ:PNT) is an Indiana based biotechnology firm with several cancer treatments in Phase 3 trials. The firm made a big announcement in October when it revealed that the pharma giant Eli Lilly will acquire it to expand its cancer treatment efforts.

Insider Monkey scoured through 910 hedge funds for their second quarter of 2023 shareholdings to find that 25 had bought POINT Biopharma Global Inc. (NASDAQ:PNT)’s shares.

7. Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Number of Hedge Fund Investors In Q2 2023: 26

P/E Ratio: 16.65

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) is a backend biotechnology company that provides firms with equipment to develop drugs and vaccines. Its shares saw quite a bit of action in July 2023 when rumors suggested that pharma giant Merck is interested in a takeover.

During 2023’s June quarter, 36 out of the 910 hedge funds polled by Insider Monkey were the firm’s investors. Joel Ramin’s 12 West Capital Management is Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)’s largest investor through a $41.7 million stake that comes courtesy of 3.3 million shares.

6. Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Number of Hedge Fund Investors In Q2 2023: 29

P/E Ratio: 9.85

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) develops treatments for adults with sleeping disorders. The firm is currently seeking to expand its operational portfolio by buying another biotechnology company.

During Q2 2023, 29 out of the 910 hedge funds tracked by Insider Monkey had invested in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY). Out of these, the biggest stakeholder is Albert Cha and Frank Kung’s Vivo Capital due to a $91.7 million stake.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), United Therapeutics Corporation (NASDAQ:UTHR), and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) are some top biotechnology stocks that hedge funds are piling into.

Click here to continue reading and check out 5 Cheap Biotech Stocks Smart Investors Are Piling Into.

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Published on June 23, 2025 at by Inan Dogan, PhD

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

AI is eating the world—and the machines behind it are ravenous.

Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink.

Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and building the digital future. But there’s one urgent question few are asking:

Where will all of that energy come from?

AI is the most electricity-hungry technology ever invented. Each data center powering large language models like ChatGPT consumes as much energy as a small city. And it’s about to get worse.

Even Sam Altman, the founder of OpenAI, issued a stark warning:

“The future of AI depends on an energy breakthrough.”

Elon Musk was even more blunt:

“AI will run out of electricity by next year.”

As the world chases faster, smarter machines, a hidden crisis is emerging behind the scenes. Power grids are strained. Electricity prices are rising. Utilities are scrambling to expand capacity.

And that’s where the real opportunity lies…

One little-known company—almost entirely overlooked by most AI investors—could be the ultimate backdoor play. It’s not a chipmaker. It’s not a cloud platform. But it might be the most important AI stock in the US owns critical energy infrastructure assets positioned to feed the coming AI energy spike.

As demand from AI data centers explodes, this company is gearing up to profit from the most valuable commodity in the digital age: electricity.

The “Toll Booth” Operator of the AI Energy Boom

It owns critical nuclear energy infrastructure assets, positioning it at the heart of America’s next-generation power strategy.
It’s one of the only global companies capable of executing large-scale, complex EPC (engineering, procurement, and construction) projects across oil, gas, renewable fuels, and industrial infrastructure.
It plays a pivotal role in U.S. LNG exportation—a sector about to explode under President Trump’s renewed “America First” energy doctrine.

Trump has made it clear: Europe and U.S. allies must buy American LNG.

And our company sits in the toll booth—collecting fees on every drop exported.

But that’s not all…

As Trump’s proposed tariffs push American manufacturers to bring their operations back home, this company will be first in line to rebuild, retrofit, and reengineer those facilities.

AI. Energy. Tariffs. Onshoring. This One Company Ties It All Together.

While the world is distracted by flashy AI tickers, a few smart investors are quietly scooping up shares of the one company powering it all from behind the scenes.

AI needs energy. Energy needs infrastructure.

And infrastructure needs a builder with experience, scale, and execution.

This company has its finger in every pie—and Wall Street is just starting to notice.

Wall Street is noticing this company also because it is quietly riding all of these tailwinds—without the sky-high valuation.

While most energy and utility firms are buried under mountains of debt and coughing up hefty interest payments just to appease bondholders…

This company is completely debt-free.

In fact, it’s sitting on a war chest of cash—equal to nearly one-third of its entire market cap.

It also owns a huge equity stake in another red-hot AI play, giving investors indirect exposure to multiple AI growth engines without paying a premium.

And here’s what the smart money has started whispering…

The Hedge Fund Secret That’s Starting to Leak Out

This stock is so off-the-radar, so absurdly undervalued, that some of the most secretive hedge fund managers in the world have begun pitching it at closed-door investment summits.

They’re sharing it quietly, away from the cameras, to rooms full of ultra-wealthy clients.

Why? Because excluding cash and investments, this company is trading at less than 7 times earnings.

And that’s for a business tied to:

The AI infrastructure supercycle
The onshoring boom driven by Trump-era tariffs
A surge in U.S. LNG exports
And a unique footprint in nuclear energy—the future of clean, reliable power

You simply won’t find another AI and energy stock this cheap… with this much upside.

This isn’t a hype stock. It’s not riding on hope.

It’s delivering real cash flows, owns critical infrastructure, and holds stakes in other major growth stories.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 100+% Return within 12 to 24 months.

We’re now offering month-to-month subscriptions with no commitments.

For a ridiculously low price of just $9.99 per month, you can unlock our in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

Access to our Detailed Report on our AI, Tariffs, and Nuclear Energy Stock with 100+% potential upside within 12 to 24 months
BONUS REPORT on our #1 AI-Robotics Stock with 10000% upside potential: Our in-depth report dives deep into our #1 AI/robotics stock’s groundbreaking technology and massive growth potential.
One New Issue of Our Premium Readership Newsletter: You will also receive one new issue per month and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.
One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149
Bonus Content: Premium access to members-only fund manager video interviews
Ad-Free Browsing: Enjoy a month of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
Lifetime Price Guarantee: Your renewal rate will always remain the same as long as your subscription is active.
30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Subscribe Now!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!

Insider Monkey Ads

A New Dawn is Coming to U.S. Stocks

Published on June 13, 2025 at by Insider Monkey Staff

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…

Insider Monkey Ads

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up

12 Cheap Biotech Stocks Smart Investors Are Piling Into

Published on October 20, 2023 at 12:08 pm by Ramish Cheema in Hedge Funds, News

Cheap Biotech Stocks Smart Investors Are Piling Into

12. Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

11. BioNTech SE (NASDAQ:BNTX)

10. Zymeworks Inc. (NASDAQ:ZYME)

9. Halozyme Therapeutics, Inc. (NASDAQ:HALO)

8. POINT Biopharma Global Inc. (NASDAQ:PNT)

7. Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

6. Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Published on June 23, 2025 at by Inan Dogan, PhD

Here’s why this is a deal you can’t afford to pass up:

A New Dawn is Coming to U.S. Stocks

Published on June 13, 2025 at by Insider Monkey Staff

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Premium

Log In

Sign Up

12 Cheap Biotech Stocks Smart Investors Are Piling Into

Published on October 20, 2023 at 12:08 pm by Ramish Cheema in Hedge Funds, News

Share

Cheap Biotech Stocks Smart Investors Are Piling Into

12. Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

11. BioNTech SE (NASDAQ:BNTX)

10. Zymeworks Inc. (NASDAQ:ZYME)

9. Halozyme Therapeutics, Inc. (NASDAQ:HALO)

8. POINT Biopharma Global Inc. (NASDAQ:PNT)

7. Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

6. Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Share

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Published on June 23, 2025 at by Inan Dogan, PhD

Here’s why this is a deal you can’t afford to pass up:

A New Dawn is Coming to U.S. Stocks

Published on June 13, 2025 at by Insider Monkey Staff